Walleye Capital
PTCT icon

Walleye Capital’s PTC Therapeutics PTCT Stock Holding History

Walleye Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,900
Closed -$448K – 4863
2025
Q4 		$448K Buy
5,900
+4,000
+211% +$291K ﹤0.01% 3024
2025
Q3 		$117K Buy
1,900
+1,400
+280% +$72.9K ﹤0.01% 3630
2025
Q2 		$24.4K Buy
+500
New +$23.7K ﹤0.01% 4205
2024
Q2 		– Sell
-1,500
Closed -$43.6K – 5918
2024
Q1 		$43.6K Buy
+1,500
New +$42K ﹤0.01% 4726
2023
Q2 		– Sell
-5,900
Closed -$286K – 4780
2023
Q1 		$286K Buy
+5,900
New +$270K ﹤0.01% 2175
2020
Q1 		– Sell
-3,300
Closed -$158K – 1507
2019
Q4 		$158K Buy
3,300
+2,500
+313% +$106K 0.01% 1213
2019
Q3 		$27K Sell
800
-2,700
-77% -$118K ﹤0.01% 1700
2019
Q2 		$158K Buy
+3,500
New +$138K 0.02% 1059

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Walleye Capital's PTCT Position: Q1 2026 in Review

Walleye Capital sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 18,074 shares — an estimated $1.37M sold.

Walleye Capital first reported a position in PTCT in Q2 2019 and held it in 15 quarters. The position peaked at $4.97M in Q4 2024. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Walleye Capital reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 18,074 PTC Therapeutics shares in Q1 2026, an estimated $1.37M.
  • Walleye Capital first reported a position in PTC Therapeutics in Q2 2019 and held it in 15 quarters.
  • Walleye Capital's PTC Therapeutics position peaked at $4.97M in Q4 2024.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.